Advertisement

Brain Tumor Pathology

, Volume 31, Issue 1, pp 1–10 | Cite as

Relationship of 14-3-3zeta (ζ), HIF-1α, and VEGF expression in human brain gliomas

  • Wei-Dong Cao
  • Nobuyuki KawaiEmail author
  • Keisuke Miyake
  • Xiang ZhangEmail author
  • Zhou Fei
  • Takashi Tamiya
Original Article

Abstract

Accumulating evidence suggests that tissue hypoxia and apoptosis play important roles in the malignant progression of brain tumors. We investigated the relationship of 14-3-3zeta (an apoptosis-related protein), HIF-1α, and VEGF immunohistochemistry, and evaluated the prognostic value of their expression in human brain gliomas. A semiquantitative analysis of the immunoreactivity scores (IRSs) of the 14-3-3zeta, HIF-1α, and VEGF proteins was performed in 27 patients with various grades of gliomas. The IRS of 14-3-3zeta increased with tumor grade, with grade IV gliomas having the highest score (P < 0.05). Similar results were found for the IRSs of HIF-1α and VEGF (P < 0.05). A significant positive correlation was found between the IRSs of 14-3-3zeta and HIF-1α, 14-3-3zeta and VEGF, and HIF-1α and VEGF (P < 0.001 for all). The survival time of HIF-1α in grade III and grade IV glioma patients with low IRSs (0–6) was significantly longer than that in such glioma patients with high IRSs (8–12) (P < 0.05). These data indicate that 14-3-3zeta, HIF-1α, and VEGF are involved in the same cascade of the malignant progression of gliomas. Further studies will elucidate their detailed role in the malignant progression of glioma, and will contribute to the development of a new treatment strategy for this lethal disease.

Keywords

Glioma 14-3-3zeta HIF-1α VEGF 

Notes

Acknowledgments

This study was supported by Grants-in-Aid for Scientific Research (C) (21591845) and (B) (22390277) from the Ministry of Education, Science and Culture of Japan. Wei-Dong Cao is a research doctor from the Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, China. This study was also supported by a Grant in China (National Nature Science Foundation of China, no: 81072083).

Conflict of interest

The authors have no conflict of interest.

References

  1. 1.
    Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol Mech Dis 1:97–117CrossRefGoogle Scholar
  2. 2.
    Louis DN, Ohgaki H, Wiestler OD (2007) WHO classification of tumors of the central nervous system, vol 1, 4th edn. IARC, LyonGoogle Scholar
  3. 3.
    Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93–108PubMedCrossRefGoogle Scholar
  4. 4.
    Rajendran JG, Mankoff DA, O’Sullivan F et al (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252PubMedCrossRefGoogle Scholar
  5. 5.
    Brat DJ, Castellano-Sanchez AA, Hunter SB et al (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64:920–927PubMedCrossRefGoogle Scholar
  6. 6.
    Fischer I, Gagner JP, Law M et al (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297–310PubMedCrossRefGoogle Scholar
  7. 7.
    Tsang RW, Fyles AW, Milosevic M et al (2000) Interrelationship of proliferation and hypoxia in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 46:95–99PubMedCrossRefGoogle Scholar
  8. 8.
    Slomiany MG, Rosenzweig SA (2006) Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 318:666–675PubMedCrossRefGoogle Scholar
  9. 9.
    Cao WD, Zhang X, Zhang JN et al (2006) Immunocytochemical detection of 14-3-3 in primary nervous system tumors. J Neurooncol 77:125–130PubMedCrossRefGoogle Scholar
  10. 10.
    Yang X, Cao W, Lin H et al (2009) Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci 276:54–59PubMedCrossRefGoogle Scholar
  11. 11.
    Sunayama J, Tsuruta F, Masuyama N et al (2005) JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 170:295–304PubMedCrossRefGoogle Scholar
  12. 12.
    Yang X, Cao W, Zhang L et al (2012) Targeting 14-3-3zeta in cancer therapy. Cancer Gene Ther 19:153–159PubMedCrossRefGoogle Scholar
  13. 13.
    Neal CL, Xu J, Li P et al (2012) Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 31:897–906PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Karar J, Gerniglia GJ, Lindsten T et al (2012) Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translocation and increases cell death under hypoxia. Cancer Biol Ther 13:1102–1111PubMedCrossRefGoogle Scholar
  15. 15.
    Lin YM, Huang YL, Fong YC et al (2012) Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. PLoS One 7:e50924. doi: 10.1371/journal.pone.0050924 PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Remmele W, Hildebrand U, Hienz HA et al (1986) Comparative histological, histochemical, immunohistochemical and biochemical studies on estrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch 409:127–147Google Scholar
  17. 17.
    Cao L, Cao W, Zhang W et al (2008) Identification of 14-3-3 protein isoforms in human astrocytoma by immunohistochemistry. Neurosci Lett 432:94–99PubMedCrossRefGoogle Scholar
  18. 18.
    Aitken A (2006) 14-3-3 proteins: a historic overview. Semin Cancer Biol 16:162–172PubMedCrossRefGoogle Scholar
  19. 19.
    Berardi S, Caivano A, Ria R et al (2012) Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene 31:2258–2269PubMedCrossRefGoogle Scholar
  20. 20.
    Kobayashi H, Ogura Y, Sawada M et al (2011) Involvement of 14-3-3 proteins in the second epidermal growth factor-induced wave of Rac1 activation in the process of cell migration. J Biol Chem 286:39259–39268PubMedCrossRefGoogle Scholar
  21. 21.
    Oksvold MP, Huitfeldt HS, Langdon WY (2004) Identification of 14-3-3zeta as an EGF receptor interacting protein. FEBS Lett 569:207–210PubMedCrossRefGoogle Scholar
  22. 22.
    Cao W, Yang X, Zhou J et al (2010) Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis 15:230–241PubMedCrossRefGoogle Scholar
  23. 23.
    Yang X, Cao W, Zhou J et al (2011) 14-3-3zeta positive expression is associated with a poor prognosis in patients with glioblastoma. Neurosurgery 68:932–938PubMedGoogle Scholar
  24. 24.
    Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317–335PubMedCrossRefGoogle Scholar
  25. 25.
    Kaur B, Khwaja FW, Severson EA et al (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134–153PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Oliver L, Olivier C, Marhuenda FB et al (2009) Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol 2:263–284PubMedCrossRefGoogle Scholar
  27. 27.
    Mashiko R, Takano S, Ishikawa E et al (2011) Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image. J Neurooncol 102:43–50PubMedCrossRefGoogle Scholar
  28. 28.
    Gillespie DL, Whang K, Ragel BT et al (2007) Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 13:2441–2448PubMedCrossRefGoogle Scholar
  29. 29.
    Argyriou AA, Giannopoulou E, Kalofonos HP (2009) Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology 77:1–11PubMedCrossRefGoogle Scholar
  30. 30.
    Machein MR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50:109–120PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2013

Authors and Affiliations

  1. 1.Department of Neurological Surgery, Faculty of MedicineKagawa UniversityMiki-cho, Kita-gunJapan
  2. 2.Department of Neurosurgery, Xijing HospitalFourth Military Medical UniversityXi’anChina

Personalised recommendations